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Infection Frequently Triggers Thrombotic
Microangiopathy in Patients with Preexisting Risk
Factors: A Single-Institution Experience
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1Clinical Apheresis Unit, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
2Health Protection Scotland, Clifton House, Glasgow, United Kingdom
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Glasgow, United Kingdom
Thrombotic microangiopathies are rare conditions characterized by microangiopathic hemolytic anemia, micro
thrombi, and multiorgan insult. The disorders, which include hemolytic uremic syndrome and thrombotic throm
bocytopenic purpura, are often acute and life threatening. We report a retrospective analysis of 65 patients pre
senting to our institution from 1997 to 2008 with all forms of thrombotic microangiopathy. Therapeutic plasma
exchange was a requirement for analysis and 65 patients were referred to our institution; 66% of patients were
female and median age at presentation was 52 years. Bacterial infection was the most commonly identified etiol
ogic factor and in the multivariate model was the only significant variable associated with survival outcome
(odds ratio 5.1, 95% confidence interval, 1.2 21.7). As infection can be considered a common trigger event for
thrombotic microangiopathy, patients with hepatobiliary sepsis may benefit from elective cholecystectomy. We
conclude that bacterial infection frequently triggers TTP and other thrombotic microangiopathies in patients with
preexisting risk factors and propose a model for the development of these syndromes.
Key words: infection; thrombotic thrombocytopenic purpura; thrombotic microangiopathy; hemolytic ure-
mic syndrome; bacterial sepsis; cholelithiasis
INTRODUCTION
The thrombotic microangiopathies (TMA), mainly
comprising thrombotic thrombocytopenic purpura
(TTP) and hemolytic uremic syndrome (HUS) as well
as some rarer syndromes, are infrequent disorders char-
acterized by microangiopathic hemolytic anemia,
microthrombi, and multiorgan injury. Although the eti-
ology of HUS is multifactorial, infection with vero-
toxin-producing Escherichia coli (VTEC), particularly
E. coli O157, has been clearly established as the pre-
dominant cause of diarrhea-positive (D1) HUS, with
childhood HUS most often following bloody diarrhea
caused by VTEC [1,2]. In contrast, TTP frequently
occurs in adults with a number of identifiable precipi-
tants. Studies have implicated the von Willebrand fac-
tor (VWF) cleaving metalloprotease, ADAMTS13 (a
disintegrin and metalloprotease with thrombospondin
Type 1 motif, number 13), as being important in the
pathogenesis of TTP [3–5]. Deficiency of ADAMTS13
can be genetic (Upshaw-Schulman syndrome) or
acquired through autoimmune production of antibodies
to the metalloprotease [6]. In the last decade, the syn-
drome of atypical HUS (aHUS or D(-)HUS) has
become recognized as one with predominantly renal
involvement, no diarrheal prodrome, and mutations in
complement factor genes CFH, CFI, or MCP in
approximately 50% of cases [7–9]. In both HUS and
TTP, although initial endothelial damage is believed to
arise by different mechanisms, the end result is exten-
sive microvascular platelet deposition with resultant
thrombocytopenia and occlusion of small vessels. Sev-
eral rarer TMA syndromes, including HELLP syn-
drome of pregnancy [10] posttransplant TTP associated
with calcineurin inhibitors, and cancer-associated
thrombotic microangiopathy can also lead to a similar
clinical picture [11].
However, ADAMTS13 deficiency or complement
gene abnormalities alone cannot explain all the variable
manifestations of TTP and aHUS, which range from
minimal symptoms to multiorgan failure [12,13]. Dis-
ease pathogenesis may also involve additional unknown
genetic factors and/or environmental triggers. Recently,
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it was demonstrated that verotoxin was able to induce
a TTP-like syndrome in ADAMTS13-knockout mice,
suggesting a role for this toxin as a potential trigger for
TTP [14], although the same group found that lipopoly-
saccharide (LPS)-induced mortality was not affected by
ADAMTS13 or VWF deficiency [15]. We previously
reported population-based epidemiologic surveillance
of TMAs and noted severe sepsis as one of the most
frequent precipitants of TTP [2].
LPS, a component of the cell walls of Gram-nega-
tive bacteria is a potent mediator of inflammation [16]
and evokes powerful responses, leading to activation of
acute phase proteins including interleukin-6, a cytokine
which contributes to the body’s defense by inducing
fever, a common presentation of TTP. Furthermore,
LPS has been postulated to activate platelets and/or
damage endothelium and, therefore, precipitate platelet
consumption during HUS, which may contribute to
TMA [17]. Previous evidence has shown that the onset
of TTP can be triggered by pancreatitis [18] or abdomi-
nal surgery for conditions such as cholelithiasis, where
presumably Gram-negative bacteria may cause systemic
infection and the subsequent thrombotic process [19].
The Clinical Apheresis Unit (CAU) at Gartnavel
Hospital in Glasgow is a referral center for treatment
of patients with TMA. We retrospectively reviewed
cases with all forms of TMA at our institution from
1997 to 2008 and determined that bacterial infection
frequently triggers TTP and other TMAs in patients
with preexisting risk factors, which may include auto-
immune disease, antihypertensive therapy, antiplatelet
agents, pregnancy, and/or genetic determinants.
PATIENTS AND METHODS
All cases of TMA (TTP, HUS, or rarer syndromes)
were identified at a single apheresis unit on referral for
therapeutic plasma exchange (TPE), as a consecutive-
patient series from October 1997 to September 2008 in-
clusive. Information on presenting symptomatology,
medical history (including any recent infections), medi-
cations used in the month before diagnosis, family his-
tory, health behavior, and demographics were obtained
by questionnaire. Medical records were reviewed for
laboratory and clinical data. Patients were consented
for HIV testing before plasma exchange; all were HIV
negative. We included all patients who fulfilled the fol-
lowing minimum criteria: microangiopathic hemolytic
anemia (low hemoglobin with evidence of red cell
fragmentation on blood film), thrombocytopenia (plate-
lets < 150 3 109/L), and elevated lactate dehydrogen-
ase (LDH; at least 150% of upper end of normal LDH
range of referring hospital at diagnosis). Additionally, a
coagulation screen and fibrinogen assay was carried
out at the time of referral to exclude other causes of
thrombocytopenia such as disseminated intravascular
coagulation (DIC).
Assays for ADAMTS13, anti-ADAMTS13 antibody
and genetic abnormalities in Complement Factors H and
I are increasingly used worldwide to help differentiate
TTP (low ADAMTS13 levels 1/2 anti-ADAMTS13
antibody) from aHUS (frequently associated with com-
plement factor gene mutations); however, such assays
have not until very recently been available routinely in
Scotland. We therefore defined TTP, HUS or other
TMA syndromes on clinical grounds as described below.
Patients were considered to have typical HUS if they
had developed TMA following culture-confirmed infec-
tion with E. coli O157 or pneumococcus (in children), or
if there was a well documented pro-dromal episode of
bloody diarrhea in the absence of positive cultures. For
the remaining patients, clinical distinction between
aHUS and TTP was on the basis of predominantly renal
involvement (aHUS) or predominantly hematological/
neurologic involvement (TTP). Thirteen patients were
considered to have typical HUS (nine patients with
documented E. coli O157 infection, two children with
documented prodromal pneumococcal septicaemia, and
two adults with well-documented prodromal bloody di-
arrhea). Of the remaining 52 patients, 12 were consid-
ered to have atypical HUS on clinical grounds and 38
were considered to have TTP (of whom two had postpar-
tum TTP and two had posttransplant TTP). Two patients
had cancer-associated thrombotic microangiopathy, with
metastatic malignancy being diagnosed after plasma
exchange had been commenced.
Statistical Methods
Associations between categorical variables were
investigated using Chi-squared tests or Fisher’s exact
test, and odds ratios and 95% confidence intervals are
presented. Quantitative variables were analyzed using
t-tests or Mann-Whitney tests as appropriate for the
distribution of the data. Variables which were signifi-
cant at the 5% level were then used in a logistic regres-
sion model to determine the independent predictors of
survival. Spearman’s correlation coefficient (two-tailed)
was also used to measure hematological variables. All
analyses were done using Minitab (version 15).
RESULTS
Between January 1, 1997 and December 31, 2008,
65 patients fulfilled the case definition of TMA and
were subsequently treated at our institution. This figure
corresponds to an annualized incidence of 0.4 cases per
100,000. The median age of cases was 52 (range 1–
81); 43 cases were female (66%). Of the cases for
whom discharge outcome data were available (n 5
54), 28 fully recovered (52%), 14 (26%) had residual
renal impairment (of which seven were dialysis de-
pendent) and 10 patients died (19%). One patient expe-
rienced a cerebrovascular accident and another patient
suffered residual neurologic complications.
Preexisting Risk Factors for Development of
Thrombotic Microangiopathy
From our institutional experience, we report that
development of TMA is preceded by a number of pre-
existing risk factors including infection, malignant
hypertension and immunomodulating drugs (Table I).
Laboratory-confirmed or clinically suspected infection
was the predominant identified risk factor (69% of
cases, Table II) although only 14% were attributed to
infection with E. coli O157. Thirty-nine of 65 (60%)
cases reported gastrointestinal symptoms ranging from
transient diarrhea and/or vomiting to acute bloody diar-
rhea and abdominal pain. Of the 39 patients, nine cases
had positive stool cultures for E. coli O157, two cases
had acute bloody diarrhea considered to be infectious
despite negative cultures, and a further 14 had a pro-
dromal history of gastro-intestinal symptoms, which
were microbiologically negative for gastro-intestinal
pathogens including E. coli O157. For the remaining
14 patients with gastrointestinal symptoms, these could
be explained by other infections (e.g., pancreatitis) or
noninfectious causes (Table II).
Factors Associated with Survival Outcome
In the multivariate model, infection (OR 5.1,
95%CI, 1.2–21.7) was the only variable which
remained using backwards selection and was signifi-
cantly associated with survival outcome (Table III). Ta-
ble III shows odds ratios, P-values and 95% confidence
intervals for categorical variables in relation to sur-
vival. Patients presenting with gastrointestinal symp-
toms were significantly associated with an improved
survival outcome (OR 5.0, 95%CI, 1.1–22.3).
Factors Associated with Residual Renal
Impairment
In the multivariate model, there was evidence to
suggest that higher serum creatinine levels at referral
were associated with residual renal impairment (P <
0.03) and that higher peak serum creatinine levels were
significantly associated with residual renal impairment
(P < 0.02; Table IV). We also observed a positive cor-
TABLE II. Details of Laboratory Confirmed and Suspected Infections Observed in TMA Cohort
Infection type
Clinical sub group
of TMA (n 5 45) Clinical details
Gram positive bacterial
infection (confirmed)
HUS (2) Pneumococcal septicemia
aHUS (2) Staphylococcus aureus (infected sebaceous cyst; elbow abscess)
TTP (2) Streptococcus pyogenes (throat infection; post partum
endometritis with beta hemolytic Streptococcus)
Gram negative bacterial
infection other than
E. coli O157 (confirmed)
aHUS (2) E. coli bacteremia (n 5 4: presumed sources infected
pancreatic pseudocyst post pancreatitis; suspected
ischaemic bowel post cardiogenic shock; soft tissue
abscess; no obvious source in one patient)
TTP (3) Klebsiella urinary tract infection
E. coli O157 HUS (9) E. coli O157 cultured from stool
Viral infection TTP (5) Hepatitis C infection (n 5 2)
CMV re activation post HSC transplant
Recent HSV encephalitis
MMR vaccine (live attenuated vaccine)
18 days prior to presentation with TTP
Clinically suspected
infection no
organism identified
HUS (2) Gastro intestinal upset considered likely to be infectious,
without bloody diarrhoea (n 5 14)
aHUS (4) Bloody diarrhea but negative cultures (n 5 2)
TTP (14) Pancreatitis (n 5 2)
Suspected cholelithiasis (transiently abnormal LFTs and
suggestive clinical picture)
Severe upper respiratory infection treated with antibiotics
TABLE I. Preexisting Factors in Development of Thrombotic
Microangiopathy
Variable n Cases (%)
Infection 65 45 69.2
E. coli O157 cultured 9 13.8
Gastro intestinal symptoms 65 39 60.0
Diarrhea 30 46.9
Bloody diarrhea 10 15.6
Vomiting 19 29.7
Antihypertensive drugs 50 17 34.0
Systemic lupus erythematosus or
other autoimmune condition
64 9 14.1
Aspirin or other anti platelet
agents
50 8 16.0
Cyclosporin/tacrolimus 65 8 12.3
Previous TMA 65 6 9.2
Cholelithiasis 65 4 6.1
relation between referral platelet count and serum cre-
atinine levels (r 5 0.38, P 5 0.002).
Patients with More Than One Potential Risk
Factor
Several patients appeared to have more than one
premorbid risk factor (examples given in Table V).
The common pattern involved infection as an acute
trigger in a patient with a preexisting predisposition to
TMA in the form of multisystem autoimmune disease,
administration of calcineurin inhibitors, or presumed
genetic predisposition to TMA on the basis of several
previous episodes.
DISCUSSION
This retrospective 12-year review of our institution’s
experience with TMA patients undergoing plasma
exchange was aimed at elucidating etiologic variables
associated with disease development. One potential
strength of this study is that we present data on a large
number of consecutive patients from a single institution
with inclusion criteria of referral for plasma exchange
and a blood picture consistent with thrombotic micro-
angiopathy (regardless of presumed underlying cause).
Our patient population of 65 cases was comparable
with that of other series published in the literature [20–
22]. Our consistent approach over the years has previ-
ously allowed us to aid identification of significant pre-
disposing factors to TMA [2].
This study provides a range of data including epide-
miology, demography, clinical parameters, and out-
comes, and it suggests that in the West of Scotland,
bacterial infection is one of the most common precipi-
tants of TMA in those with preexisting risk factors.
Infection with VTEC such as E. coli O157 is recog-
nized to be the predominating risk factor for D1HUS,
with serotype O157 being the most common [1]. Pneu-
mococcal-HUS is also a well-recognized etiologic fac-
tor in pediatric patients [23]. However, other studies
have previously shown that there may be a role for
other pathogens as potential triggers of TMA [24,25]
and studies with animal models of TTP have also sug-
gested this [14]. Our current findings support a signifi-
cant role for infections other than E. coli O157 as com-
mon precipitants of TMA, including both clinically
defined TTP and aHUS. However, in the absence of
routine ADAMTS13 assays the assignment of patients
to either TTP or aHUS on clinical grounds may be
somewhat imprecise.
Few previous studies have investigated potential pre-
morbid risk factors or trigger factors for TTP and
aHUS. A multicenter prospective epidemiologic study
of TTP is underway in North America, with prelimi-
nary findings having been published [26]. Although the
main aim of the SERF project was to elucidate the role
of anti-platelet agents as potential risk factors for
TMA, other risk factors identified included recent anti-
biotic use, history of connective tissue disease, and a
family history of thrombocytopenia or stroke. It seems
TABLE IV. Comparisons for Quantitative Variables Associated with Residual Renal Impairment
Variable Renal impairment n Minimum Median Maximum P value
Age (years) Yes 49 1 45 79
No 7 26 54 72 0.69
Platelet count first referral Yes 49 6 38 151
No 7 27 63 88 0.26
LDH first referral Yes 46 252 1537 5678
No 7 942 1918 3702 0.63
Creatinine first referral Yes 47 80 230 2480
No 7 243 450 1050 0.03
Peak creatinine Yes 47 78 296 2480
No 7 390 628 1050 0.02
Discharge creatinine Yes 38 50 129 800
No 7 96 220 325 0.41
No. of plasma exchanges Yes 48 1 9 62
No 7 8 11 27 0.15
TABLE III. Comparisons for Quantitative Variables Associated
with Survival (n 5 54)
Variable Comparison OR P value 95% CI
Gender male vs. female 2.3 0.33 0.4, 12.1
Fever yes vs. no 2.7 0.37 0.3, 24.2
CNS symptoms yes vs. no 0.4 0.24 0.1, 1.8
Abnormal LFTs yes vs. no 1.1 0.91 0.2, 4.4
Gastro intestinal symptoms yes vs. no 5.0 0.035 1.1, 22.3
Diarrhea yes vs. no 2.3 0.26 0.5, 10.2
Bloody diarrhea yes vs. no 0.6 0.61 0.1, 3.7
Vomitinga 0.02
SLE or ‘‘other’’ yes vs. no 1.5 0.74 0.2, 13.7
Cholelithiasisa 1.00
Cyclosporin/tacrolimus yes vs. no 0.5 0.47 0.1, 3.1
Previous TMAa 0.57
Anti platelet drugs yes vs. no 0.4 0.31 0.1, 2.5
Antihypertensive drugs yes vs. no 0.2 0.12 0.04, 1.4
Infection yes vs. no 5.1 0.03 1.2, 21.7
E. coli O157 cultured yes vs. no 0.6 0.61 0.1, 3.7
aAll with yes survived.
probable that recent antibiotic use in the SERF study
group is a surrogate marker for acute infection immedi-
ately preceding presentation with TMA. There are two
extant TTP registries that have published findings: the
Oklahoma TTP-HUS Registry [27] and the South East
England TTP Registry [5]. The former registry is rele-
vant in that, like our own patient group, this is a clini-
cally defined group of all patients with TMA referred
for plasma exchange. However, despite a number of
valuable lessons (particularly regarding what subgroups
of patients are more likely to respond to plasma
exchange), the focus of the Oklahoma registry is on the
correlation of clinical and laboratory features with
treatment outcome, rather than with potential premor-
bid or prodromal risk factors. The South East England
Registry did consider potential precipitating causes and
found defined infection (Mycoplasma) in only a single
patient, although 2% of patients had pancreatitis and/or
hepatobiliary sepsis. However, these patients were not
specifically questioned about premorbid infections or
Fig. 1. Hypothesis of thrombotic microangiopathy as a multifactorial process. [Color figure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
TABLE V. Five Patients with a Clear History Suggesting an Infective Trigger for TMA in an Individual with a Preexisting
Risk Factor
Age & Gender Clinical summary Eventual outcome Presumed biological mechanism of TMA
54, F On tacrolimus after previous single
lung transplant. Presented in acute
renal failure with TMA (HUS) after
confirmed E. coli O157 gastroenteritis
Full recovery (including renal
recovery) after 11 plasma
exchanges
E. coli O157 infection in patient taking
calcineurin inhibitor
38, F Preexisting severe longstanding SLE.
Developed TMA after episode of
confirmed cholelithiasis
Full recovery after 13 plasma
exchanges
Probable Gram negative bacteraemia in
patient with preexisting multisystem
autoimmune disease
45, M Two previous episodes of TMA 15
and 32 years earlier. Developed
TMA after episode of cholecystitis
Full recovery after 10 plasma
exchanges
Probable Gram negative bacteraemia
in patient with presumed genetic
susceptibility to TMA
70, F Known Wegener’s granulomatosis,
in remission on immunosuppressive
therapy. Developed TMA after
confirmed coliform bacteraemia
(not E. coli) in association with
gastroenteritis
TMA resolved after 36 plasma
exchanges, but remains
dialysis dependent
Proven Gram negative bacteraemia
in patient with preexisting multisystem
autoimmune disease
44, F Known SLE; developed TMA after
episode of pancreatitis (which
appeared related to underlying
cholelithiasis)
Full recovery after 11 plasma
exchanges
Probable Gram negative bacteraemia
in patient with preexisting multisystem
autoimmune disease
recent antibiotic usage, compared with our patient
group so the incidence of premorbid infection may
have been underestimated. It is interesting that pancrea-
titis or hepatobiliary sepsis was also a common premor-
bid factor in our study [18] and pancreatitis has also
been reported as a potential precipitant for TMA in a
series of patients from the Oklahoma Registry [28].
One potential confounding factor may be misdiagno-
sis of DIC associated with acute sepsis as TMA. How-
ever, as has been reported by other groups [24], the
clinical picture observed in our cohort was almost
always the development of TMA during the apparent
recovery phase and not in the acute infectious phase.
Excepting two of our patients, all had an entirely nor-
mal coagulation screen and fibrinogen at the time of
referral for plasma exchange making DIC unlikely.
In the past few years, efforts have been made to cor-
relate plasma levels of ADAMTS13 activity and sever-
ity of TTP [5]. The largest series to date was published
from the Oklahoma registry and demonstrated that
severe ADAMTS13 deficiency was not sensitive to
detect all patients with thrombotic microangiopathy
who benefitted from plasma exchange [12]. In our
study, we were unable to assess the role of
ADAMTS13 due to the assay not being available
within Scotland and the associated financial constraints
of performing the assay elsewhere in the United King-
dom. We are hopeful of addressing this in the near
future by participating in a proposed national UK TTP
registry (Dr. M. Scully, personal communication).
In our experience, there is some overlap between the
three syndromes of TTP, aHUS, and D1HUS, and we
suggest infection (other than with E. coli O157) as
being a plausible common trigger for TTP and aHUS.
We have frequently observed more than one potential
premorbid risk factor for TMA in the same patient.
We, therefore, propose a model for the development of
TMA, where TMA can be considered a final common
outcome of increased adhesion between platelets and
microvascular endothelium (Fig. 1). TMAs can arise by
a variety of mechanisms, although one or two tend to
predominate in an individual patient. Once a critical
level of adhesion between platelets and microvascular
endothelium is exceeded, the presence of activated pla-
telet microthrombi in the microvasculature induces
ongoing platelet activation and adhesion via a positive
feedback loop, resulting in a thrombotic microangio-
pathic cascade.
Our results have potential implications for patients
who have recovered from an episode of TMA, given
that both TTP and aHUS have a significant risk of
relapse. If infection is considered a common trigger
event, then the risk of recurrence in patients with a his-
tory of TMA might be reduced by prompt treatment of
any bacterial infections, coupled with careful monitor-
ing of platelet counts and LDH following any infectious
episode. There may also be an argument for elective
cholecystectomy in patients where hepatobiliary sepsis
appears to be a premorbid trigger event. The anti-CD20
monoclonal antibody, Rituximab, is increasingly used
in the treatment of TTP [5]. Although systemic immu-
nosuppression associated with this drug is generally
mild and the short-term relapse risk of TTP is reduced
[29], there is the theoretical potential that patients may
become increasingly susceptible to bacterial infections
which may in turn, increase the long-term relapse risk
of TMA. This should be investigated in large-scale pro-
spective studies such as the UK TTP registry.
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